HLB Pharmaceutical Co., Ltd.

HLB Pharmaceutical Co., Ltd. is a South Korean biopharmaceutical company specializing in the research, manufacture, and distribution of pharmaceutical products. The company is headquartered in Namyangju, Gyeonggi-do, South Korea. HLB Pharmaceutical is part of the HLB Group, a biopharmaceutical conglomerate involved in various sectors, including pharmaceuticals, medical devices, diagnostics, cell therapy, and digital healthcare. The HLB Group is headquartered in Seoul, South Korea. The ultimate owner of HLB Pharmaceutical is HLB Co., Ltd., which oversees the group's diverse operations. The company is led by CEO Jae Hyung Park and has been recognized for its commitment to innovation in the pharmaceutical industry. HLB Pharmaceutical's research and development efforts focus on long-acting injectables and regenerative functional dermal fillers, aiming to enhance its capabilities as a global pharmaceutical entity. The company operates multiple facilities, including its headquarters in Namyangju, a Seoul office, and a plant in Hyangnam, Hwaseong-si, all located in South Korea. HLB Pharmaceutical has also been involved in significant financial activities, such as a private placement of convertible bonds in August 2022, with participation from JW Holdings Corporation, Prime Life & Health Co., Ltd., and DongKoo Bio & Pharma Co., Ltd. This funding was intended to support the company's growth and development initiatives. The company's website provides further information on its products, research areas, and corporate activities.